Britain's' Medicines And Healthcare Products Regulatory Agency Says Astrazeneca's Diabetes Drug Bydureon, Sanofi's Lixisenatide And Eli Lilly's Dulaglutide Also Included In The Review
Portfolio Pulse from Benzinga Newsdesk
The UK's Medicines and Healthcare Products Regulatory Agency is reviewing AstraZeneca's diabetes drug Bydureon, Sanofi's Lixisenatide, and Eli Lilly's Dulaglutide.
July 26, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AstraZeneca's diabetes drug Bydureon is under review by the UK's health regulator.
The review of AstraZeneca's diabetes drug Bydureon by the UK's health regulator could potentially lead to changes in its approval status, which could impact the company's revenues and stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
The review of diabetes drugs by the UK's health regulator could impact the UK's healthcare sector.
The review of diabetes drugs by the UK's health regulator could lead to changes in the approval status of these drugs, which could impact the revenues of the companies involved and the overall UK healthcare sector.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
NEGATIVE IMPACT
Eli Lilly's diabetes drug Dulaglutide is under review by the UK's health regulator.
The review of Eli Lilly's diabetes drug Dulaglutide by the UK's health regulator could potentially lead to changes in its approval status, which could impact the company's revenues and stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100